^
    2ms
    LAG-3 antagonists for cancer treatment: an updated patent review (2020-2025). (PubMed, Expert Opin Ther Pat)
    The trend shows that monospecific antibodies against LAG-3 continue to be the main antagonists, followed by multispecific t, treatment methods using known LAG-3 antagonists, LAG-3 binding peptides, and LAG-3 binding small molecules. The monospecific antibodies encelimab, miptenalimab, and the bispecific antibodies tobemstomig, IBI323, ABL501, fanastomig, and FS118 are added, during this period, to the potential drugs targeting LAG-3.
    Review • Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule)
    |
    FS118 • ABL501 • IBI-323 • encelimab (TSR-033) • miptenalimab (BI 754111) • tobemstomig (RG6139)
    4ms
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (clinicaltrials.gov)
    P1, N=463, Active, not recruiting, Tesaro, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2025 --> Mar 2027
    Enrollment closed • Trial primary completion date • First-in-human
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • encelimab (TSR-033)
    almost2years
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (clinicaltrials.gov)
    P1, N=475, Recruiting, Tesaro, Inc. | Trial completion date: Jul 2025 --> Apr 2027 | Trial primary completion date: Dec 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • First-in-human
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • encelimab (TSR-033)
    almost2years
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (clinicaltrials.gov)
    P1, N=475, Recruiting, GlaxoSmithKline
    New P1 trial • Metastases
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • encelimab (TSR-033)
    almost3years
    CITRINO: Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=111, Completed, Tesaro, Inc. | Active, not recruiting --> Completed | Trial completion date: Nov 2022 --> Feb 2023 | Trial primary completion date: Nov 2022 --> Jun 2022
    Trial completion • Trial completion date • Trial primary completion date
    |
    RAS wild-type
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • Jemperli (dostarlimab-gxly) • leucovorin calcium • encelimab (TSR-033)
    3years
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (clinicaltrials.gov)
    P1, N=475, Recruiting, Tesaro, Inc. | Trial completion date: Oct 2024 --> Jul 2025 | Trial primary completion date: Oct 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • First-in-human
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • encelimab (TSR-033)
    over4years
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (clinicaltrials.gov)
    P1, N=369, Recruiting, Tesaro, Inc. | Trial completion date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2023 --> Oct 2023
    Trial completion date • Trial primary completion date • First-in-human
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • encelimab (TSR-033)
    over4years
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (clinicaltrials.gov)
    P1, N=369, Recruiting, Tesaro, Inc. | Trial completion date: Oct 2023 --> Jun 2024 | Trial primary completion date: Oct 2021 --> Jun 2023
    Trial completion date • Trial primary completion date • First-in-human
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • encelimab (TSR-033)
    over5years
    Quantifying the efficacy of checkpoint inhibitors on CD8 cytotoxic T cells for immunotherapeutic applications via single-cell interaction. (PubMed, Cell Death Dis)
    We also found that the combination of TSR-042 and TSR-033 appears to synergistically increase tumor cell killing and the single-cell level. This study provides a novel single-cell-based assessment of the impact these checkpoint inhibitors have on cellular interactions with CD8 T cells.
    Clinical • Journal • Checkpoint inhibition
    |
    LAG3 (Lymphocyte Activating 3)
    |
    Jemperli (dostarlimab-gxly) • encelimab (TSR-033)
    over5years
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (clinicaltrials.gov)
    P1, N=369, Recruiting, Tesaro, Inc. | Trial primary completion date: Apr 2022 --> Jul 2021
    Trial primary completion date • PD(L)-1 Biomarker • First-in-human
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • encelimab (TSR-033)
    over5years
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (clinicaltrials.gov)
    P1, N=369, Recruiting, Tesaro, Inc. | Trial primary completion date: Jul 2021 --> Apr 2022
    Trial primary completion date • PD(L)-1 Biomarker • First-in-human
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • encelimab (TSR-033)
    over5years
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (clinicaltrials.gov)
    P1, N=369, Recruiting, Tesaro, Inc. | N=873 --> 369 | Trial completion date: Jun 2022 --> Jul 2023
    Enrollment change • Trial completion date • PD(L)-1 Biomarker • First-in-human
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • encelimab (TSR-033)